Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALB | P02768 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.31 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277774 | 0.86 | ALDH1A1 (0.57) | LMNAALBALDH1A1POLBADRA1A | |
| SCHEMBL4285526 | 0.83 | LMNA (0.39) | LMNAALBALDH1A1POLBADRA1A | |
| SCHEMBL11899425 | 0.82 | LMNA (0.43) | LMNAALBALDH1A1POLBADRA1A | |
| Elvucitabine SCHEMBL3298257 | 0.82 | ALB (0.55) | LMNAALBALDH1A1POLBADRA1A | |
| Elvucitabine SCHEMBL1649928 | 0.82 | ALB (0.55) | LMNAALBALDH1A1POLBADRA1A | |
| Dexelvucitabine SCHEMBL599014 | 0.82 | ALB (0.55) | LMNAALBALDH1A1POLBADRA1A | |
| SCHEMBL10211502 | 0.81 | LMNA (0.40) | LMNAALBALDH1A1POLBADRA1A | |
| SCHEMBL10211489 | 0.81 | LMNA (0.40) | LMNAALBALDH1A1POLBADRA1A | |
| SCHEMBL10211504 | 0.81 | LMNA (0.39) | LMNAALBALDH1A1POLBADRA1A | |
| SCHEMBL10211492 | 0.80 | LMNA (0.39) | LMNAALBALDH1A1POLBADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140031309-A1 | Beta-L-N4 Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2014-01-30 | — | — | US | disclosed |
| US-20090105186-A1 | Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105186-A1 | Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | TYMP, ENTPD5, NUDT1 | LMNA 256/4885ALB 3936/4885ALDH1A1 2004/4885 |
| US-20140031309-A1 | Beta-L-N4 Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | SAMHD1, TYMP, NUDT1 | LMNA 560/4885ALB 4316/4885ALDH1A1 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.